Calgary, Alberta, Canada, August 11, 2025 – Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), announces the award of 142,987 deferred share units (“DSUs”) to two of Marvel’s directors, in lieu of cash payment for directors’ fees.| Marvel Biosciences
The post Marvel Announces the Second of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide Following Cessation of Drug Treatment appeared first on Marvel Biosciences.| Marvel Biosciences
Recruitment of adults with fragile X syndrome to test NM-1001, a microdose of the psychedelic psilocybin is ongoing in Ontario, Canada.| Fragile X News Today
Children with fragile X syndrome have had problems with their academic performance and social interactions since the COVID-19 pandemic.| Fragile X News Today
The LivJoy Foundation is funding a four-year postdoctoral fellowship for a scientist at USC who will study fragile X syndrome in females.| Fragile X News Today